Trisalus Life Sciences, INC Schedule 13G passive stakes

First Light Asset Management, LLC and Mathew P. Arens have jointly filed a Schedule 13G, reporting beneficial ownership of 10.74% of TriSalus Life Sciences, Inc. common stock as of June 30, 2026.

James J. Pallotta has reported beneficial ownership of 3,188,711 shares, representing 5.2% of TriSalus Life Sciences, Inc. common stock, including shares underlying warrants.

First Light Asset Management and Mathew P. Arens have reported an 8.75% beneficial ownership stake in TriSalus Life Sciences, Inc. via a Schedule 13G filing.

Utmost Group PLC has reported a beneficial ownership of 3,503,385 shares, representing 5.71% of TriSalus Life Sciences' common stock as of March 31, 2026.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 4.09% beneficial ownership in Trisalus Life Sciences, Inc. as of September 30, 2025.

Utmost Group PLC reported an increased beneficial ownership of 6.79% in TriSalus Life Sciences, Inc. common stock as of September 30, 2025, primarily through a preferred share conversion.

Utmost Group PLC's beneficial ownership in TriSalus Life Sciences Inc. has decreased to 0.0529% due to an increase in the issuer's outstanding shares.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has disclosed a beneficial ownership of 5.29% in Trisalus Life Sciences, Inc., totaling 2,000,000 shares.